Nutra Pharma is providing an update on the sales and marketing efforts of TCN as they begin their global marketing campaign for Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin™.
Coral Springs, FL. – December 20, 2012 - Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin™.
In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin™ to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. Sales to individual consumers have already begun in the US, Europe, Asia and Africa. Additionally, TCN has scheduled marketing efforts in the US that will include internet, radio and television.
“The Nyloxin products represent a wonderful opportunity for our distributors,” commented Dalton Johnson, CEO of TCN. “These are pain-relievers and anti-inflammatory drugs that have provided great results with almost no risk of side effects. We believe that we can achieve significant sales through our distributors as well as sales continuity as they use and order the product monthly," he concluded.
Nyloxin™ is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin™ is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin™ is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
“TCN has been consistently increasing the public awareness of Nyloxin,” said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We believe that they may create significant market penetration and subsequent sales growth over the next several months,” he concluded.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.nutrapharma.com
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The publication of Nutra Pharma's patent and trademarks in India should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.